Chronic inflammatory bowel diseases

Clinical information

The most important chronic inflammatory bowel diseases (CIBD) include ulcerative colitis (UC) and Crohn's disease (CD).

UC belongs to the CIBD with autoimmune reactions against the mucosa and submucosa of the colon or rectum and increased immune reactions against the intestinal flora. A genetic susceptibility for UC is assumed and the disease is supposed to be triggered by certain environmental factors. The inflammation spreads continuously from the rectum, that is from the anal region upwards.

CD is classified as an autoimmune disease of the intestinal mucosa and is among the CIBD with a high recurrence rate. The chronic granulomatous inflammation, which can affect the whole digestive tract from the oral cavity to the anus, is found in most cases only in the lower small intestine (terminal ileum) and the large intestine (colon), very rarely in the oesophagus and mouth. CD is characterised by discontinuous, segmental attack on the intestinal mucosa. Resulting thereof, several sections of the intestine may be affected simultaneously, being interrupted by healthy sections.

Diagnostics

Initial differentiation between irritable bowel syndrome and CIBD can be achieved by non-invasive antigen detection of calprotectin in stool and thus provide a decisive precharacterisation of bowel-associated inflammation (see chapter Calprotectin). Alongside the single IIF tests, the high diagnostic demands on differentiated CIBD diagnostics are also met by various highly specific mosaics (CIBD profiles) specifically developed for serological diagnostics of the autoimmune intestinal diseases CD and UC.

Autoantibodies against the exocrine pancreas are a reliable marker for CD. They have a high disease-specific significance due to their organ specificity, disease association and frequently high serum concentration. Due to the fact that the inflammation of the intestinal wall in CD is caused by the autoantigens contained in the pancreas secretion, particularly the proteoglycans CUZD1 and GP2, the determination of autoantibodies against the pancreas antigens rPAg1 (CUZD1) and/or PAg2 (GP2) using IIFT represents a new dimension in serological CD diagnostics. Antibodies against Saccharomyces cerevisiae (ASCA) enrich the serodiagnostics for CD by a further specific parameter.

Autoantibodies against intestinal goblet cells, which occur exclusively in UC, are pathognomonic markers for this autoimmune disease. The target antigen responsible for UC has not yet been exactly identified. The serological determination of autoantibodies against DNA-bound lactoferrin contributes significantly to the diagnosis of CIBD, particularly of UC.

Selected Products

Method
Parameter
Substrate
Species
EUROLINE
Autoimmune Gastrointestinal Diseases IgA
(tissue transglutaminase (endomysium), gliadin-analogue
fusion peptide (GAF-3X), mannan (ASCA))
EUROLINE
EUROLINE
Autoimmune Gastrointestinal Diseases IgG
(tissue transglutaminase (endomysium),
gliadin-analogue fusion peptide (GAF-3X),
parietal cell antigen (PCA) separately
Intrinsic factor, mannan (ASCA))
EUROLINE
IIFT
CIBD Screen 3
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)
intestinal goblet cells
3 BIOCHIPs per field:
transfected cells
goblet cells
control transfection

EU 90
EU 80
EU 90
IIFT
CIBD Profile 3
upper row:
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)

intestinal goblet cells
pANCA
DNA-bound lactoferrin (pANCA)
ANCA negative
bottom row:
Saccharomyces cerevisiae


transfected cells
control transfection
goblet cells
granulocytes (EOH)
LFS granulocytes
HSS granulocytes

fungal smear


EU 90
EU 90
EU 80
human
human
human

S. cerevisiae
IIFT
CIBD Profile 7
upper row:
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)
intestinal goblet cells
pANCA

bottom row:
Saccharomyces cerevisiae


transfected cells
goblet cells
granulocytes (EOH)
control transfection

fungal smear


EU 90
EU 80
human
EU 90

S. cerevisiae
ELISA
Saccharomyces cerevisiae
antigen-coated
microplate wells
IIFT
Saccharomyces cerevisiae
fungal
smear
Saccharomyces
cerevisiae
Stool Dosage Tubes, ready for use
Use in combination with EQ / LQ 6831 W
stool dosage tubes, unfilled
Use in combination with EQ / LQ 6831 W
ELISA
calprotectin
determination in stool
Antibody-coated
microplate wells
ChLIA
Control set
calprotectin
determination in stool
2 x 0.5 ml control 1/2
ChLIA
calprotectin
determination in stool
Antibody-coated
magnetic particles
ChLIA
IDS Calprotectin Calibrator Set
2 x 0.5 ml calibrator 1/2/3/4/5
ChLIA
IDS Calprotectin Control Set
3 x 0.5 ml control 1/2
ChLIA
IDS Calprotectin
Antibody-coated
magnetic particles
IDS Calprotectin Extraction Device




Use in combination with IS-AI26000
Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Europe
Asia
Oceania
Middle East & Africa